Top 10 US Synthetic Biology Companies

Twist Bioscience is the world's leading synthetic DNA manufacturer, with a $1.5B market cap and capacity to produce 10 billion base pairs of synthetic DNA per year using its silicon-based DNA synthesis platform. Its silicon chip synthesis process reduces DNA synthesis costs by 1,000x versus traditional methods, democratising genome-scale experiments for 3,000+ research and biopharma clients. The 2025 FDA clearance of Twist's NGS oncology panel validated its DNA synthesis precision for clinical diagnostics, opening a $5B+ addressable market.

Colossal Biosciences has raised $225M on a mission to de-extinct the woolly mammoth, thylacine (Tasmanian tiger), and dodo using CRISPR gene editing and artificial wombs. Founded in 2021 by entrepreneur Ben Lamm and geneticist George Church, Colossal achieved its first major milestone in 2025 by creating cold-adapted elephant embryos with 57 mammoth-specific gene edits — the most complex multiplex gene editing ever performed in a large mammal. Its conservation genomics platform is simultaneously being applied to save the Asian elephant and northern white rhinoceros from extinction.

Mammoth Biosciences has raised $150M+ and is co-founded by CRISPR Nobel laureate Jennifer Doudna to develop ultra-sensitive CRISPR-based diagnostics and next-generation gene editing tools. Its DETECTR platform detects infectious disease biomarkers in under 30 minutes without PCR equipment, enabling point-of-care diagnostics for 50+ pathogen targets including SARS-CoV-2, HPV, and monkeypox. The 2025 CE-IVD marking in Europe for its first CRISPR diagnostic kit established Mammoth as the first company to commercialise regulatory-approved CRISPR diagnostics.

Caribou Biosciences has raised $225M to develop off-the-shelf CRISPR CAR-T cell therapies that could be manufactured in advance and shipped to cancer patients within 48 hours, eliminating the 4-6 week personalised manufacturing window of autologous therapies. Its chRDNA guide technology achieves superior editing precision versus standard CRISPR-Cas9, reducing off-target edits by 5x in clinical-grade cell manufacturing. The 2025 Phase 2 data for CB-010, its allogeneic CAR-T for relapsed B-cell lymphoma, showed 60% complete response rate — outperforming standard-of-care chemotherapy benchmarks.

Inscripta has raised $200M to commercialise the world's first digital genome engineering platform, enabling massively parallel gene editing experiments that previously required $10M+ in equipment for under $500K per experiment run. Its Onyx platform performs 10,000+ simultaneous CRISPR edits per day, accelerating metabolic engineering for biofuels, enzymes, and therapeutic proteins. The 2025 partnership with Novozymes embedded Inscripta's technology in the world's largest industrial enzyme development pipeline, targeting $1B in new enzyme sales by 2027.

Modern Meadow has raised $53M to produce biofabricated leather and performance materials using yeast-fermented collagen proteins that replicate the properties of animal leather without slaughter or petrochemical processing. Its Zoa material is used by luxury fashion brands seeking sustainability credentials without compromising on texture or durability, with 15+ fashion brand partnerships active in 2025. A 2025 scale-up agreement with a NASDAQ-listed chemical company secured 500-tonne annual production capacity, enabling commercial-scale retail availability for the first time.

Pivot Bio has raised $430M to engineer nitrogen-fixing microbes that colonise crop roots and replace synthetic nitrogen fertiliser, reducing agricultural emissions from the 120M-tonne annual nitrogen fertiliser market. Its PROVEN 40 product, applied to 6M+ acres in 2024, delivers nitrogen equivalent to 40 lbs/acre of synthetic fertiliser while cutting nitrous oxide emissions by 10% per field. The 2025 USDA organic certification for PROVEN 40 opened the $15B+ organic farming market, doubling Pivot's total addressable opportunity.

Mycoworks has raised $125M to commercialise Fine Mycelium — a patented mushroom-root leather alternative grown in 10 days with the tensile strength and luxury feel of premium calfskin. Its Reishi material is used by Hermes, Stella McCartney, and GM's Cadillac division, validating mycelium leather for both luxury goods and automotive interiors. The 2025 opening of a 70,000-square-foot South Carolina production facility marked Mycoworks' transition from artisan-scale to automotive-volume output, targeting 5M square metres of annual production capacity by 2027.

Zymergen pioneered the application of machine learning to strain engineering before its 2021 NASDAQ IPO and subsequent $300M acquisition by Ginkgo Bioworks in 2022, consolidating the two largest AI-biology platforms in the US. Its materials science IP — including bio-based polyimide films for flexible electronics and optical components — now sits within Ginkgo's broader advanced materials programme. The Zymergen-derived bio-optics pipeline is targeting a $2B+ specialty materials market for foldable displays and AR/VR optics, with first commercial samples shipped to three consumer electronics OEMs in 2025.

Twist Bioscience is the world's leading synthetic DNA manufacturer, with a $1.5B market cap and capacity to produce 10 billion base pairs of synthetic DNA per year using its silicon-based DNA synthesis platform. Its silicon chip synthesis process reduces DNA synthesis costs by 1,000x versus traditional methods, democratising genome-scale experiments for 3,000+ research and biopharma clients. The 2025 FDA clearance of Twist's NGS oncology panel validated its DNA synthesis precision for clinical diagnostics, opening a $5B+ addressable market.

Colossal Biosciences has raised $225M on a mission to de-extinct the woolly mammoth, thylacine (Tasmanian tiger), and dodo using CRISPR gene editing and artificial wombs. Founded in 2021 by entrepreneur Ben Lamm and geneticist George Church, Colossal achieved its first major milestone in 2025 by creating cold-adapted elephant embryos with 57 mammoth-specific gene edits — the most complex multiplex gene editing ever performed in a large mammal. Its conservation genomics platform is simultaneously being applied to save the Asian elephant and northern white rhinoceros from extinction.

Mammoth Biosciences has raised $150M+ and is co-founded by CRISPR Nobel laureate Jennifer Doudna to develop ultra-sensitive CRISPR-based diagnostics and next-generation gene editing tools. Its DETECTR platform detects infectious disease biomarkers in under 30 minutes without PCR equipment, enabling point-of-care diagnostics for 50+ pathogen targets including SARS-CoV-2, HPV, and monkeypox. The 2025 CE-IVD marking in Europe for its first CRISPR diagnostic kit established Mammoth as the first company to commercialise regulatory-approved CRISPR diagnostics.

Caribou Biosciences has raised $225M to develop off-the-shelf CRISPR CAR-T cell therapies that could be manufactured in advance and shipped to cancer patients within 48 hours, eliminating the 4-6 week personalised manufacturing window of autologous therapies. Its chRDNA guide technology achieves superior editing precision versus standard CRISPR-Cas9, reducing off-target edits by 5x in clinical-grade cell manufacturing. The 2025 Phase 2 data for CB-010, its allogeneic CAR-T for relapsed B-cell lymphoma, showed 60% complete response rate — outperforming standard-of-care chemotherapy benchmarks.

Inscripta has raised $200M to commercialise the world's first digital genome engineering platform, enabling massively parallel gene editing experiments that previously required $10M+ in equipment for under $500K per experiment run. Its Onyx platform performs 10,000+ simultaneous CRISPR edits per day, accelerating metabolic engineering for biofuels, enzymes, and therapeutic proteins. The 2025 partnership with Novozymes embedded Inscripta's technology in the world's largest industrial enzyme development pipeline, targeting $1B in new enzyme sales by 2027.

Modern Meadow has raised $53M to produce biofabricated leather and performance materials using yeast-fermented collagen proteins that replicate the properties of animal leather without slaughter or petrochemical processing. Its Zoa material is used by luxury fashion brands seeking sustainability credentials without compromising on texture or durability, with 15+ fashion brand partnerships active in 2025. A 2025 scale-up agreement with a NASDAQ-listed chemical company secured 500-tonne annual production capacity, enabling commercial-scale retail availability for the first time.

Pivot Bio has raised $430M to engineer nitrogen-fixing microbes that colonise crop roots and replace synthetic nitrogen fertiliser, reducing agricultural emissions from the 120M-tonne annual nitrogen fertiliser market. Its PROVEN 40 product, applied to 6M+ acres in 2024, delivers nitrogen equivalent to 40 lbs/acre of synthetic fertiliser while cutting nitrous oxide emissions by 10% per field. The 2025 USDA organic certification for PROVEN 40 opened the $15B+ organic farming market, doubling Pivot's total addressable opportunity.

Mycoworks has raised $125M to commercialise Fine Mycelium — a patented mushroom-root leather alternative grown in 10 days with the tensile strength and luxury feel of premium calfskin. Its Reishi material is used by Hermes, Stella McCartney, and GM's Cadillac division, validating mycelium leather for both luxury goods and automotive interiors. The 2025 opening of a 70,000-square-foot South Carolina production facility marked Mycoworks' transition from artisan-scale to automotive-volume output, targeting 5M square metres of annual production capacity by 2027.

Zymergen pioneered the application of machine learning to strain engineering before its 2021 NASDAQ IPO and subsequent $300M acquisition by Ginkgo Bioworks in 2022, consolidating the two largest AI-biology platforms in the US. Its materials science IP — including bio-based polyimide films for flexible electronics and optical components — now sits within Ginkgo's broader advanced materials programme. The Zymergen-derived bio-optics pipeline is targeting a $2B+ specialty materials market for foldable displays and AR/VR optics, with first commercial samples shipped to three consumer electronics OEMs in 2025.